Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Human Papillomavirus (HPV) Vaccines
May 05, 2022
Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade. There are currently three branded vaccines for HPV: Cervarix, Gardasil, and Gardasil 9. Merck & Co’s Gardasil, a quadrivalent vaccine, was first-to-market with its debut in 2006, narrowly ahead of the 2007 release of GlaxoSmithKline’s rival bivalent vaccine, Cervarix. Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs). In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Human papillomavirus (HPV) Prevention (Antiviral, Vaccines)|